Zoetis raises guidance as core franchises offset Librela weakness

Transcript intelligence

What changed

Compared with the prior quarter, management moved from maintaining full-year guidance to raising it. The current analysis also shows stronger emphasis on the Simparica franchise and international livestock demand, alongside a clearer warning that Librela adoption is lagging expectations.

Guidance delta

Management raised full-year organic revenue growth guidance to 6.5%-8% and organic net income growth guidance to 5.5%-7.5%, from the prior quarter's maintained outlook of 6%-8% and 5%-7%.

Key takeaways

• Management reported 8% organic revenue growth and 10% adjusted net income growth on an operational basis in Q2.
• Simparica, including Simparica Trio, remained a central growth driver, while international livestock demand was also strong.
• Librela adoption lagged expectations; management is using veterinary education and Phase IV studies to support uptake.
• The pipeline includes a long-acting osteoarthritis pain monoclonal antibody and ongoing livestock vaccine development.

Management priorities

• Support Librela adoption through veterinary education and third-party studies.
• Expand alternative and retail channels for companion-animal products.
• Advance the long-acting osteoarthritis pain monoclonal antibody and livestock vaccine pipeline.
• Maintain a pace of at least one major product approval annually across therapeutic areas.